Lenacapavir sodium is an antiretroviral medication used for two main purposes: the treatment of multidrug-resistant HIV-1 infection and pre-exposure prophylaxis (PrEP) to prevent HIV-1 infection. It is a first-in-class, long-acting HIV-1 capsid inhibitor. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sunlenca and Yeztugo. Its PubChem CID is 153435888.
Lenacapavir sodium
| CAS No | 2283356-12-5 |
|---|---|
| Molecular Formula | C39H31ClF10N7NaO5S2 |
| Molecular Weight | 990.30 g/mol |
| Synonyms | sodium [4-chloro-7-[2-[(1S)-2-(3,5-difluorophenyl)-1-[[2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetyl]amino]ethyl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)-3-pyridinyl]-1-(2,2,2-trifluoroethyl)indazol-3-yl]-methylsulfonylazanide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lenacapavir sodium is an antiretroviral medication used for two main purposes: the treatment of multidrug-resistant HIV-1 infection and pre-exposure prophylaxis (PrEP) to prevent HIV-1 infection.
The listed CAS number is 2283356-12-5.
The listed molecular formula is C39H31ClF10N7NaO5S2.
The listed molecular weight is 990.30 g/mol.
sodium [4-chloro-7-[2-[(1S)-2-(3,5-difluorophenyl)-1-[[2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetyl]amino]ethyl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)-3-pyridinyl]-1-(2,2,2-trifluoroethyl)indazol-3-yl]-methylsulfonylazanide.
The source lists Sunlenca and Yeztugo.